DOCSLIB.ORG

Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N-Formimidoyl Thienamycin CHARLES E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N-Formimidoyl Thienamycin CHARLES E ANTIMICROBIAi, AGENTS AND CHEMOTHERAPY, OCt. 1981, I). 553-555 Vol. 20, No. 4 0066-4804/81/ 100553-0:3$02.00/() Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N-Formimidoyl Thienamycin CHARLES E. CHERUBIN,'* MICHAEL L. CORRAI)O,2 MARCELINO F. SIERRA, MYLES E. GOMBERT,2 AND) MICHAEL SHULMAN' The Infectious Disease Service, Brooklyn -Jewish Hospital, Brooklyn, Newl York 112,381; and The Infectious Disease Division2 and The Department of Pathology, 3Downstate Medical Center, State Jniversity of New York, Brooklyn, New York 11203 Received 27 March 1981/Accepted 25 June 1981 The activities of cefotaxime, moxalactam, MK 0787 (N-formimidoyl thiena- mycin), ampicillin, oxacillin, vancomycin, and clindamycin were compared against gram-positive cocci. MK 0787 was the most active and moxalactam was the least active of these drugs, except against methicillin-resistant Staphylococcus aureus, where vancomycin was most active, and penicillin-resistant pneumococci, where cefotaxime was more active. A number of beta-lactam antibiotics with Laboratories), vancomycin (Eli Lilly & Co.), clin- broadened coverage and enhanced activity damycin (The Upjohn Co.), cefotaxime against gram-negative bacilli have been devel- (Hoechst Roussel Pharmaceuticals, Inc.), and oped recently (2, 6, 8-10). If these compounds cephalothin (Eli Lilly & Co.) in sterile water possess high activity against common gram-pos- (6,400 fig/ml) and moxalactam (Eli Lilly & Co.) itive pathogens, they might be considered for in 1 M phosphate buffer (pH 7; 6,400 tig/ml) empirical use as the sole therapeutic agent until were stored at -70°C until used. N-Formimidoyl identification and susceptibility reports on cul- thienamycin (MK 0787) (Merck & Co., Inc.) was ture specimens are obtained. We report herein prepared daily in sterile water (2,560 tig/ml). the results of a comparison of the activities of The preparation of the inocula and definitions three relatively new beta-lactams, cefotaxime, of the minimum inhibitory and minimum bac- moxalactam, and MK 0787 (N-formimidoyl tericidal concentrations (MIC and MBC, respec- thienamycin), as well as oxacillin, ampicillin, tively) have previously been described (3). Using vancomycin, and clindamycin, against gram-pos- the microtiter system, we performed susceptibil- itive bacteria associated with endocarditis and ity testing for all isolates except methicillin-re- bacteremia. sistant staphylococci (3). Methicillin-resistant The 157 isolates examined in this study were staphylococci were tested by a broth macrotiter obtained from patients with diagnosed endocar- method also previously described (3), as well as ditis, intravascular catheter-associated bactere- the microtiter method, which was read at 24 and mia, cellulitis, pneumonia, neonatal bacteremia 48 h. Mueller-Hinton broth (MHB; BBL Micro- and meningitis, hepatic abscess, cholangitis, and biology Systems) was utilized for all tests except bacteremias of obscure origin. All isolates except those on the beta-hemolytic streptococci and S. the penicillin-resistant pneumococci were ob- pneumoniae, where MHB supplemented by 10% tained from multiple (two or more) blood cul- laked sheep's blood was utilized. Inocula of 5 x tures from patients at the Brooklyn Jewish, 10" colony-forming units per ml and 5 x 10' Kings County, and State University hospitals. colony-forming units per ml were used in suscep- The resistant pneumococci, obtained from Har- tibility testing of all isolates except the beta- riet Bernheimer, had been isolated from blood hemolytic streptococci and S. pneumoniae, and spinal fluid of South African patients. The where only the 5 x 10' colony-forming units per beta-hemolytic streptococci were grouped by ml inoculum was tested. both the Phadebact agglutination and autoclave At the MIC.,1 level, MK 0787 was either equiv- precipitation extraction methods (7). Identifica- alent in activity or more active than any other tion of each isolate was performed by conven- compound tested against each group of isolates, tional methods (1, 4, 5). except the methicillin-resistant Staphylococcus Antibiotics. Stock solutions of oxacillin aureus, where vancomycin was most active, and (Bristol Laboratories), ampicillin (Beecham the penicillin-resistant S. pneumoniae, where 5513 554 NO<I'ES ANTIMICROB. A(GFNTS CHFMOTHER. TABLE 1. MICs of variolus compounds against gram -positivte coccii Compound Range of MICS MI( Isolate (no.) (pg/mi of mnedIiunm) Group A streptococci ( 11) Oxacillin 0.03-0.5 0.06 0.15 Ampicillin <0.03-0.06 <0.0:3 0.06 Vancomwcin <0.03-0.25 <0.03 0.25 Clindanivcin <0(.3-0.25 0.06 0.06 Cefotaxime <0.03-0.125 0.06 0.125 Moxalactam 0.5-2 MK 0787 <(.0 1 -0.06 <().(). 0.06 Group B streptococci (8) Oxacillin 0.03-0.5 0.06 (0.5 0.06 (0.125 Ampicillin <().0.3-0.125 ().()( Vancomycin <t).03-0. 125 0.06 (0.125 Clindanwcin 0.06-0.5 ((.5 Cefotaxime <().0:3-0.25 (0.25 Moxalactamn 2-4 4 MK (n787 <0.0 1 -(0.0:3 0.06 Gro)up C and G streptococci (6) Oxacillinl 0.0:3-0.5 0.06 Ampicillin <0.0:3-0.25 ((.063 (0.25 Vanconivcill 0.06-0.5 0.0:3 (0.25 Clindamnvcin <().03-0.5 (0.125 Cefotaxime <0(.0:3-0. 125 (0.125 Moxalactam 2-8 <0.06 8 MK ((787 <0.0 1 <0.06 (.0 1 Str-eptococcus faecalis (:3 1) Cephalothin 8-:32 1 6 :32 Ampicillinl <(0.5-) <(0.5 <0.5 \ancomrycin <0.5-1 ().(); 1 Clindamnvcin 4-64 .32 Cefotaxime 8->16 >16 Moxalactam 16->16 <0.53 >16 MK 0787 0.125-0.5 ((.5 Viridans streptococci (17) Oxacillinl <(0.03-0.06 ().()t Ampicillin <(0((3-0.25 t).25 Vancomrcin <0.03-0.5 ((.125 0.25 Clindarnvcin <0.03-0.5 0.06 0).06 Cefotaxime <0.03-0.5 0).125 Moxalactam 0.5-2 MK 0787 <(0( 1 <((1 <(). 19 1) S. pneum0nilae, penicillin suscep- Oxacillinl 0).03-0.25 (0.125 tible (10) Ampicillin <0.03-0.125 <(.0(3 Vancomncin 0.5-2 0.0(6 Clindamycin <0.03-0). 125 <0.0:3 (0.125 Cefotaxinie <().03-0. 125 <().() 1 Moxalactam (0.06-(0.5 0.5 (0.5 MK 0787 <(0.01 <().()1 S. pneumoniae, penicillin resist- Oxacillinl 1->8 >8 ant (10) Ampicillin 1 ->8 <0.01 8 Vancomvcin 0.125-2 -::8 2 Clindamnycin 0.25-,8 Cefotaxime 0.125-0.5 t(.5 Moxalact am o.5-,8 (0.25 1 -1 MK 0787 ().( 58 Staphylococcus epidlermic/is (3() Oxacillinl 0. 125->16 ((.5 8 Ampicillin <0. 125-> 16 0.5 8 Vanconmcvin '2->16 8 Clindamvcin 0. 125->16 16 Cef'otaxinie ().06-> 16 4 I 6 VOL. 20, 1981 NOTES 555 TABLE 1.-Continued Isolate (no.) Range of MICs (Cug/ml of medium) Moxalactam 1->16 8 >16 MK 0787 <0.01->16 0.03 2 S. aureus, methicillin susceptible Oxacillin 0.125-1 0.25 0.5 (20) Ampicillin 32->32 >32 >32 Vancomycin <0.125-0.5 0.25 0.5 Clindamycin <0.125 <0.125 <0.125 Cefotaxime 0.125-2 1 1 Moxalactam 4-8 4 4 MK 0787 <0.01 <0.01 <0.01 S. aureus, methicillin resistant Oxacillin 32-128 32 32 (14) Ampicillin 8->64 32 32 Vancomycin 0.5-2 0.5 1 Clindamycin 32->64 >64 >64 Cefotaxime 8->64 >64 >64 Moxalactam >64 >64 >64 MK 0787 0.01-8 0.03 4 " MIC5) and MIC%,, MIC for 50 and 90%, respectively, of the isolates. cefotaxime was most active (Table 1). Moxalac- Gorbach. 1979. In vitro activity of LY 127935. Anti- tam, on the other hand, was either the least microb. Agents Chemother. 16:287-291. 3. Corrado, M. L., S. H. Landesman, and C. E. Cherubin. active or among the least active of the drugs 1980. Influence of inoculum size on activity of cefoper- against all isolates tested. Among drugs which azone, cefotaxime, piperacillin and N-fornmimidoyl are either beta-lactamase resistant or relatively thienamycin (MK 0787) against Pseudomonas aerlugi- so, moxalactam displayed least activity against nosa. Antimicrob. Agents Chemother. 18:893-896. 4. Facklam, R. R. 1974. Streptococci, p. 96-108. In E. H. methicillin-susceptible S. aureus. Lennette, E. H. Spaulding, and J. P. Truant (ed.), The MBCs were generally identical to the Manual of clinical microbiology, 2nd ed. American So- MIC or were only twofold higher for all drugs ciety for Microbiology, Washington, D.C. against each of the various isolates. Increasing 5. Ivler, D. 1974. Staphylococcus, p. 91-95. In E. H. Len- the inoculum to 5 x nette, E. H. Spaulding, and J. P. Truant (ed.), Manual 10' colony-forming units per of clinical microbiology, 2nd ed. American Society for ml did not significantly alter the MBCs except Microbiology, Washington, D.C. against staphylococci. There was a fourfold in- 6. Neu, H. C., N. Aswapokee, K. P. Fu, and P. Aswa- crease in the MBCs for vancomycin in 14 of 20 pokee. 1979. Antibacterial activity of a new 1-oxa ceph- alosporin compound with that of other beta-lactam isolates of aureus, methicillin-susceptible S. in compounds. Antimicrob. Agents Chemother. 16:141- 7 of 20 for clindamycin, and in 4 of 20 for 149. cefotaxime. Similar trends were seen with coag- 7. Rantz, L. A., and E. Randall. 1955. Use of autoclaved ulase-negative staphylococci for oxacillin, ampi- extracts of haemolytic streptococci for serological cillin, grouping. Stanford Med. Bull. 13:290-291. cefotaxime, and, occasionally, for MK 8. Tally, F. P., N. V. Jacobus, and S. L. Gorbach. 1978. 0787. In vitro activity of thienamycin. Antimicrob. Agents LITERATURE CITED Chemother. 14:436-438. 9. Verbist, L., and J. Verhaegen. 1981. In vitro activity of 1. Austrian, R. 1974. Streptococcus pneumoniae (pneumo- Ro 13-9904, a new beta-lactamase-stable cephalosporin.
Load more

Recommended publications
  • In Vitro and in Vivo Study of Fosfomycin in Methicillin-Resistant Staphylococcus Aureus Septicaemia
    J. Ilyg., Camb. (1980), 96, 419-423 419 Printed in Great Britain In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia BY W. Y. LAU, C. H. TEOH-CHAN,* S. T. FAN AND K. F. LAU* Government Surgical Unit, Queen Mary Hospital, and * Department of Microbiology, University of Hong Kong {Received 15 October 19S5; accepted 12 December 19S5) SUMMARY Five hundred strains of methicillin-resistant Staphylococcus aureus were tested against various anti-staphylococcal agents. Vancomycin, fusidic acid and fosfo- mycin were found to be the most effective. Only 1 strain out of 500 was resistant to fosfomycin. Three patients with methicillin-resistant Staphylococcus aureus septicaemia were successfully treated by fosfomycin. We conclude that fosfomycin could be the drug of choice for methicillin-resistant Staphylococcns aureus infection. INTRODUCTION Outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) infection are causing increasing problems in centres all over the world (Thompson & Wenzel, 1982; Editorial, 1983). There has been a gradual increase in the incidence of MRSA in our hospital in Hong Kong from 317 in 1982 (18-7% of all S. aureus isolated) to 511 in 1983 (32-7%) and 833 in 1984 (34-9%). In vitro, resistance of MRSA is often demonstrated to many anti-staphylococcal agents including the penicillins, first-generation cephalosporins, aminoglycosides, erythromycin, clindamycin and chloramphenicol (Peacock et al. 1981). Second- and third-generation cephalosporins also have poor activity in vitro (Thompson, Fisher & Wenzel, 1982) though many MRSA strains have been found to be susceptible to rifampicin, trimethoprim- sulphamethoxazole and fusidic acid (Watanakunakorn, 1983). However, clinical experience of treating serious staphylococeal infection with rifampicin and trimethoprim-siilphamethoxazole is limited (Guenther & Wenzel, 1984) and fully resistant organisms may emerge rapidly after exposure to fusidic acid in vitro and in vivo (Watanakunakorn, 1983).
    [Show full text]
  • Thienamycin (Imipenem)
    1520 THE JOURNAL OF ANTIBIOTICS OCT. 1989 CONVERSION OF OA-6129 B2 INTO OA-6129 B2, a fermentation carbapenem product, (5i?,6^)-6-[(i?)- l -FLUOROETHYL]-7- into optically active 88617, an 8-fluorinated OXO- 3 -[(7V,Ar,Ar-TRIM ETHYL- carbapenem derivative which improved antimicro- CARBAMIMIDOYL)METHYL]THIO- bial activity and dehydropeptidase-I stability. l -AZABICYCLO[3.2.0]HEPT-2-ENE- Treatment of OA-6129B2 sodium salt 1 with 2-CARBOXYLIC ACID (88617)t /7-nitrobenzyl (PNB) bromide or pivaloyloxymethyl chloride in DMFgave /?NB ester 2 or pivaloyl- Takeo Yoshioka, AzumaWatanabe, oxymethyl (POM) ester 3 of OA-6129 B2 (Fig. 1). Noritaka Chida and Yasuo Fukagawa The two hydroxyl groups in the pantoyl moiety of OA-6129B2 were protected by isopropylidena- Central Research Laboratories, tion for differentiation from the C-8 hydroxyl Sanraku Incorporated, 4-9-1 Johnan, Fujisawa 251, Japan group. The protected compound4 or 5 was allowed to (Received for publication May 25, 1989) react with 1.2 equiv of diethylaminosulfur trifluoride (DAST)11} at -68°C in methylene chloride for 10 minutes. After the reaction mixture was diluted with Since the epoch-making discovery of thienamy- methylene chloride and washed with a saturated cin2), a numberof extensive studies have been carried aqueous sodium bicarbonate solution, silica gel out on the development of clinically useful car- column chromatography of the organic layer pro- bapenem compounds. As a result, formimidoyl- vided the desired fluorinated compound 6 or 7 thienamycin (imipenem) has recently been put on having a fluorine atom in the R configuration at C-8 the market as a combination drug (Primaxin)3) in 43 or 49% yield, respectively.
    [Show full text]
  • Profile Profile Profile Uses and Administration
    Gramicidin/lmipenem 309 Graneodin N; Graneodin; Gripaben Caramelos; Kenacomb; t Incompatibility and stability. Intipenem is unstable at Nasomicina; Neo Coltirot; Pantometilt; Proetztotal; Tosedrin �-�P.�.�� ����---········································································· alkaline or acidic pH and the commercially available injec­ (details are given in Volume B) NF; Austral.: Kenacomb; Neosporint; Otocomb Otic; Otodex; ProprielaryPreparations tion of intipenem with cilastatin sodium for intravenous Sofradex; Soframycint; Austria: Volon A antibiotikahaltigt; V alpeda. use is buffered to provide, when reconstituted, a solution Belg. : Mycolog; Polyspectran Granticidinet; Braz.: Fonergin; Single-ingredient Preparations. UK: with pH 6.5 to 7.5. Licensed product information advises Londerm-Nt; Mud; Neolon D; Omcilon-A M; Oncibel; Oncileg; against mixing with other antibacterials. Onciplust; Canad.: Ak Spor; Antibiotic Cream; Antibiotic Plus; Complete Antibiotic Ointment; Diosporint; Neosporin; Opti­ lbafloxacin (BAN, USAN, r/NN) References. cort; Optimyxin Plus; Optimyxin; Polysporin Complete; Poly­ 1. Bigley FP, et al. Compatibility of imipenem-dlastatin sodium with Am Hosp Phann 1986; 43: 2803- sporin For Kids; Polysporin Plus Pain Relief; Polysporin Triple commonly used intravenous solutions. 9. J Antibiotic; Polysporin; Polytopic; ratio-Tria comb; Sofracort; 2. Smith GB, et al. Stability and kinetics of degradation of imipenem in Soframycin; Soframycin; Triple Antibiotic Ointment; Viaderm­ Pharm 1990; 79: 732-40. aqueous
    [Show full text]
  • Radical Sam Enzymes in Thienamycin Biosynthesis
    RADICAL SAM ENZYMES IN THIENAMYCIN BIOSYNTHESIS by Daniel Roe Marous A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland December, 2015 ©Daniel Roe Marous 2015 All rights reserved Abstract Despite its broad anti-infective activity, the biosynthesis of the paradigm carbapenem antibiotic, thienamycin, remains largely unknown. Apart from the first two biosynthetic steps shared with a simple carbapenem, the pathway sharply diverges to the more structurally complex members of this class of β-lactam antibiotics like thienamycin. Existing evidence points to three putative cobalamin-dependent, radical S- adenosylmethionine (RS) enzymes, ThnK, ThnL and ThnP, potentially being responsible for assembly of the ethyl side chain at C6, bridgehead epimerization at C5, installation of the C2-thioether side chain and C2/3-desaturation. The C2 substituent has been demonstrated to be derived from stepwise truncation of coenzyme A, but the timing of these events with respect to C2—S bond formation is not known. Using in vitro reactions with synthetically-accessed substrates, we show that ThnK of the three apparent cobalamin-dependent RS enzymes performs sequential methylations to build out the C6- ethyl side chain in a stereocontrolled manner. This enzymatic reaction produced the expected RS methylase coproducts S-adenosylhomocysteine (SAH) and 5’- deoxyadenosine (5’-dA) by LC-MS and was also found to require cobalamin. For double methylation to occur, the carbapenam substrate must bear a coenzyme A-derived C2- thioether side chain, implying the activity of a prior sulfur insertion by an unidentified enzyme. Heterologous expression of thienamycin biosynthetic enzymes in Streptomyces combined with a competition bioassay now implicates ThnL in attachment of the thioether.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • PRIMAXIN (Imipenem and Cilastatin)
    • Known hypersensitivity to any component of PRIMAXIN (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ----------------------- WARNINGS AND PRECAUTIONS ----------------------­ PRIMAXIN safely and effectively. See full prescribing information • Hypersensitivity Reactions: Serious and occasionally fatal for PRIMAXIN. hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. If an allergic reaction PRIMAXIN® (imipenem and cilastatin) for Injection, for to PRIMAXIN occurs, discontinue the drug immediately (5.1). intravenous use • Seizure Potential: Seizures and other CNS adverse reactions, such Initial U.S. Approval: 1985 as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN. If focal tremors, myoclonus, or --------------------------- RECENT MAJOR CHANGES --------------------------­ seizures occur, patients should be evaluated neurologically, placed Indications and Usage (1.9) 12/2016 on anticonvulsant therapy if not already instituted, and the dosage of Dosage and Administration (2) 12/2016 PRIMAXIN re-examined to determine whether it should be decreased or the antibacterial drug discontinued (5.2). ----------------------------INDICATIONS AND USAGE ---------------------------­ • Increased Seizure Potential Due to Interaction with Valproic Acid: PRIMAXIN for intravenous use is a combination of imipenem, a penem Co-administration of PRIMAXIN, to patients receiving valproic acid antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, or divalproex sodium results in a reduction in valproic acid indicated for the treatment of the following serious infections caused by concentrations. The valproic acid concentrations may drop below designated susceptible bacteria: the therapeutic range as a result of this interaction, therefore • Lower respiratory tract infections. (1.1) increasing the risk of breakthrough seizures. The concomitant use of • Urinary tract infections.
    [Show full text]
  • The Use of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Graduate School Professional Papers 2010 The seU of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities Joshua Bryant Phillips The University of Montana Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/etd Recommended Citation Phillips, Joshua Bryant, "The sU e of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities" (2010). Graduate Student Theses, Dissertations, & Professional Papers. 1100. https://scholarworks.umt.edu/etd/1100 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES by Joshua Bryant Phillips B.S. Chemistry, Northern Arizona University, 2002 B.S. Microbiology (health pre-professional), Northern Arizona University, 2002 Presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chemistry The University of Montana June 2010 Phillips, Joshua Bryant Ph.D., June 2010 Chemistry THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES Advisor: Dr. Nigel D. Priestley Chairperson: Dr. Bruce Bowler ABSTRACT Since Alexander Fleming first noted the killing of a bacterial culture by a mold, antibiotics have revolutionized medicine, being able to treat, and often cure life-threatening illnesses and making surgical procedures possible by eliminating the possibility of opportunistic infection.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Drug Delivery System Utilizing Thermosetting Gels
    Europaisches Patentamt European Patent Office 5) Publication number: 3 126 684 Bl Dffice europeen des brevets © EUROPEAN PATENT SPECIFICATION S Date of publication of patent specification: 28.08.91 (£) Int. CI.5: A61 K 47/00, A61K9/06 © Application number: 84400982.9 g) Date of filing: 15.05.84 © Drug delivery system utilizing thermosetting gels. (is) Priority: 16.05.83 US 495238 @ Proprietor: MERCK & CO. INC. 16.05.83 US 495239 126, East Lincoln Avenue P.O. Box 2000 16.05.83 US 495240 Rahway New Jersey 07065-0900(US) 16.05.83 US 495321 @ Inventor: Haslam, John L. @ Date of publication of application: RFD 2, Box 259-B 28.11.84 Bulletin 84/48 Lawrence Kansas 66044(US) Inventor: Higuchi, Takeru © Publication of the grant of the patent: 2811 Schwarz Road 28.08.91 Bulletin 91/35 Lawrence, Kansas 66044(US) Inventor: Mlodozeniec, Arthur R. @ Designated Contracting States: 1704 St. Andrews Drive AT BE CH DE FR GB IT LI LU NL SE Lawrence Kansas 66044(US) @ References cited: AU-A- 482 821 0 Representative: Ahner, Francis et al CA-A- 1 072 413 CABINET REGIMBEAU, 26, avenue Kleber FR-A- 1 598 998 F-75116 Paris(FR) N.F.ESTRIN et al.: "CTFA COSMETIC INGRE- DIENT DICTIONARY", Third Edition, The Cos- metic, Toiletry and Fragrance Association, Inc., Washington, D.C., US; CD 00 CO CO O Note: Within nine months from the publication of the mention of the grant of the European patent, any person - may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Antimicrobial Agents and Chemotherapy
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Voliume 22 Contents for November 1982 No. 5 Mechanisms of Action: Physiological Effects Mechanism of Action of Dnacin B1, a New Benzoquinoid Antibiotic with Antitumor Properties. SEIICHI TANIDA,* TORU HASEGAWA, AND MASAHIKO YONEDA .... .................. 7735-742 Synergism Between Aminoglycosides and Cephalosporins with An- tipseudomonal Activity: Interaction Index and Killing Curve Method. HANS 0. HALLANDER,* KATHRINE DORNBUSCH, LENA GEZELIUS, KARIN JACOBSON, AND INGA KARLSSON .... 7743-752 Diffusion of j-Lactam Antibiotics Through Liposome Membranes Containing Purified Porins. YORIKo KOBAYASHI, IKUKO TAKAHASHI, AND TALJI NAKAE* ..... ...................... 7775-780 Influence of Subinhibitory Concentrations of Penicillin, Cephalothin, and Clindamycin on Staphylococcus aureus Growth in Human Phagocytic Cells. GREG R. ELLIOTT,* PHILLIP K. PETERSON, HENRI A. VERBRUGH, MARK R. FREIBERG, JQHN R. HOIDAL, AND PAUL G. QUIE ....................................... 781-784 Antibacterial Action of Gramicidin S and Tyrocidines in Relation to Active Transport, In Vitro Transcription, and Spore Out- growth. W. DANDERS, M. A. MARAHIEL,* M. KRAUSE, N. Kosui, T. KATO, N. IZUMIYA, AND H. KLEINKAUF ... ...... 7785-790 Transport of the Lipophilic Analog Minocycline Differs from That of Tetracycline in Susceptible and Resistant Escherichia coli Strains. LAURA M. MCMURRY,* JOANNE C. CULLINANE, AND STUART B. LEVY ......... ............................... 7791-799 Effect of 2-Alkynoic Acids on In Vitro Growth of Bacterial and Mammalian Cells. WATTANA KONTHIKAMEE, JOHN R. GILBERTSON,* HERMAN LANGKAMP, AND HERMAN GERSHON 8305-809 7-Hydroxytropolone: an Inhibitor of Aminoglycoside-2"-O-Adenylyl- transferase. N. E. ALLEN,* W. E. ALBORN, JR., J. N. HOBBS, JR., AND H. A. KIRST ....... ............................. 8324-831 Mechanisms of Resistance Candida albicans Resistance to 5-Fluorocytosine: Frequency of Partially Resistant Strains Among Clinical Isolates.
    [Show full text]
  • Author Section
    AUTHOR SECTION patients with new onset of fever, demographic, clinical, and laborato- Mycoplasma spp. Overall, the spectrum of antibacterial activity indi- ry variables were obtained during the 2 days after inclusion, while cates a potential role for this combination in the treatment of diffi- microbiological results for a follow-up period of 7 days were collect- cult-to-treat Gram-positive infections, including those caused by ed. Patients were followed up for survival or death, up to a maximum multidrug-resistant organisms. Since this activity extends to Gram- of 28 days after inclusion. MEASUREMENTS AND RESULTS: Of negative respiratory bacteria, quinupristin/dalfopristin may also find all patients, 95% had SIRS, 44% had sepsis with a microbiologically a role in the treatment of atypical, as well as typical, pneumonia. confirmed infection, and 9% died. A model with a set of variables all significantly (p<0.01) contributing to the prediction of mortality was Boubaker A. et al. [Investigation of the urinary tract in children in nuclear med- derived.The set included the presence of hospital-acquired fever, the icine]. Rev Med Suisse Romande. 2000; 120(3) : 251-7.p Abstract: peak respiratory rate, the nadir score on the Glasgow coma scale, and The early detection of urologic abnormalities by antenatal sonogra- the nadir albumin plasma level within the first 2 days after inclusion. phy has resulted in the investigation of many infants and neonates for This set of variables predicted mortality for febrile patients with suspicion of either obstructive uropathy or reflux nephropathy. microbiologically confirmed infection even better.The predictive val- Nuclear medicine techniques allow to assess renal parenchyma ues for mortality of SIRS and sepsis were less than that of our set of integrity, to detect pyelonephritic scars and to measure absolute and variables.
    [Show full text]
  • Individualization of Drug Therapy Considering Pharmacokinetic and Clinical Factors
    Individualization of drug therapy considering pharmacokinetic and clinical factors Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Martin Reinhold Munz aus Gaildorf Würzburg 2018 Eingereicht bei der Fakultät für Chemie und Pharmazie am Gutachter der schriftlichen Arbeit 1. Gutachter: Prof. Dr. Fritz Sörgel 2. Gutachter: Prof. Dr. Ulrike Holzgrabe Prüfer des öffentlichen Promotionskolloquiums 1. Prüfer: 2. Prüfer: 3. Prüfer: Datum des öffentlichen Promotionskolloquiums Doktorurkunde ausgehändigt am Die vorliegende Arbeit wurde am IBMP - Institut für Biomedizinische und Pharmazeutische Forschung in Nürnberg-Heroldsberg angefertigt. This thesis has been accomplished at the IBMP - Institute for Biomedical and Pharmaceutical Research in Nürnberg-Heroldsberg. Für meine Familie III IV Acknowledgement This thesis has been accomplished under the supervision of Professor Dr. Fritz Sörgel, IBMP - Institute for Biomedical and Pharmaceutical Research in Nürnberg- Heroldsberg, and Professor Dr. Ulrike Holzgrabe, Department of Pharmaceutical Chemistry, University of Würzburg, Germany. First and foremost, I greatly thank Professor Dr. Sörgel for the assignment of the scientific topic for this Ph.D. thesis, for his continuous support, advice and guidance during this thesis and for the opportunity of working on fascinating clinical projects in collaboration with the Department of Hematology and Oncology and the Department of Anesthesiology and Intensive Care Medicine of the Paracelsus Medical University, Nürnberg, Germany, and the Department for Trauma Surgery, University of Erlangen, Germany. My warmest thank you goes to Professor Dr. Ulrike Holzgrabe for supporting this Ph.D. thesis, providing feedback and guiding together with Professor Dr. Sörgel the direction and progress of this work. My warmest thank you also goes to Professor Dr.
    [Show full text]